New Research Will Target Tau’s Role in Alzheimer’s Disease
source: pixabay.com

New Research Will Target Tau’s Role in Alzheimer’s Disease

Researchers from Rensselaer Polytechnic Institute have been conducting research on tau proteins, specifically how it spreads from cell to cell. According to an article in Newswise, this team of researchers…

Continue Reading New Research Will Target Tau’s Role in Alzheimer’s Disease
New Collaboration Will Develop ARO-AAT for A1AD-Related Liver Disease
source: pixabay.com

New Collaboration Will Develop ARO-AAT for A1AD-Related Liver Disease

  In October 2020, Arrowhead Pharmaceuticals ("Arrowhead") announced a new collaboration and licensing agreement with global biopharmaceutical company Takeda Pharmaceutical Company Limited ("Takeda"). Together, the pair will develop and commercialize…

Continue Reading New Collaboration Will Develop ARO-AAT for A1AD-Related Liver Disease
The Drug Dupixent Shows Potential as an Eosinophilic Esophagitis Treatment
source: pixabay.com

The Drug Dupixent Shows Potential as an Eosinophilic Esophagitis Treatment

According to a story from GlobeNewswire, the medication dupilumab (marketed as Dupixent®) has demonstrated potential efficacy in a phase 3 clinical trial as a treatment for eosinophilic esophagitis, a rare…

Continue Reading The Drug Dupixent Shows Potential as an Eosinophilic Esophagitis Treatment
First Patient Dosed in Phase 1B Trial for Pulmonary Arterial Hypertension
https://pixabay.com/photos/animals-lemurs-wildlife-zoo-monkey-1010643/

First Patient Dosed in Phase 1B Trial for Pulmonary Arterial Hypertension

New Trial A Phase 1A trial for GMA301 was completed this year in Australia for pulmonary arterial hypertension (PAH). This trial demonstrated a positive safety profile for a range of…

Continue Reading First Patient Dosed in Phase 1B Trial for Pulmonary Arterial Hypertension
Meta Analysis Shows MMF Provides Greater Benefit to Lupus Nephritis Patients Than CYC
source: pixabay.com

Meta Analysis Shows MMF Provides Greater Benefit to Lupus Nephritis Patients Than CYC

A recent study, published in the journal Medicine, has found that Mycopheenolate mofetil (MMF) could be a more advantageous therapy for lupus nephritis than cyclophosphamide (CYC) when it comes to improving serum complement…

Continue Reading Meta Analysis Shows MMF Provides Greater Benefit to Lupus Nephritis Patients Than CYC

Data Collaboration Tool for Accelerating Rare Disease Research Celebrates Success in First Year

Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP) The RDCA-DAP, funded by the FDA, was first launched in September of 2019. Its aim was to make data more accessible for…

Continue Reading Data Collaboration Tool for Accelerating Rare Disease Research Celebrates Success in First Year
Can Doctors Predict Which Rheumatoid Arthritis Patients Will Respond to Treatment?
https://pixabay.com/en/skeleton-hand-bones-anatomy-joint-778069/

Can Doctors Predict Which Rheumatoid Arthritis Patients Will Respond to Treatment?

Not all treatments work for every patient, with rheumatoid arthritis (RA) medications being the perfect example. Disease-modifying anti-rheumatic drugs (DMARDs) are the standard of care for RA despite the fact…

Continue Reading Can Doctors Predict Which Rheumatoid Arthritis Patients Will Respond to Treatment?

New Investigative Therapy Holds Promise for Retinitis Pigmentosa in Mouse Model

Researchers from Nanoscope, thanks to funding by the NIH, have developed a protein that can effectively restore vision in mice. This study was published in Nature Gene Therapy. The Study…

Continue Reading New Investigative Therapy Holds Promise for Retinitis Pigmentosa in Mouse Model
Experimental Stargardt Disease Treatment Earns Orphan Drug and Rare Pediatric Disease Designations
source: pixabay.com

Experimental Stargardt Disease Treatment Earns Orphan Drug and Rare Pediatric Disease Designations

According to a story from PR Newswire, the biopharmaceutical company reVision Therapeutics, Inc. has just announced that its experimental therapy REV-0100 has received both Rare Pediatric Disease designation and Orphan…

Continue Reading Experimental Stargardt Disease Treatment Earns Orphan Drug and Rare Pediatric Disease Designations
Experimental Drug Earns Orphan Drug Designation for Polymyositis and Dermatomyositis
source: pixabay.com

Experimental Drug Earns Orphan Drug Designation for Polymyositis and Dermatomyositis

According to a story from Biotech 365, the biotechology company Kezar Life Sciences, Inc. recently announced that its experimental therapy KZR-616 has earned Orphan Drug designations from the US Food…

Continue Reading Experimental Drug Earns Orphan Drug Designation for Polymyositis and Dermatomyositis